Cell Separation Market Size and Trends

The Global Cell Separation Market is estimated to be valued at USD 9.90 billion in 2025 and is expected to reach USD 19.11 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.8% from 2025 to 2032.

Key Takeaways of the Cell Separation Market:

By product type, the consumables segment is expected to contribute the highest share of the market with 52.1% in 2025.
By cell type, the human cells segment is expected to contribute the highest share of the market with 49.1% in 2025.
By cell source, the adipose tissue segment is expected to contribute the highest share with 35.2% in 2025.
North America is expected to top the global market with 32.3% share, followed by Asia Pacific with 25.4% share in 2025.

Market Overview:

The demand for cell separation technologies is driven by factors such as the rising incidence of chronic and infectious diseases, along with the growing popularity of regenerative medicine and stem cell research. Additionally, increasing venture capital investments, government funding for cell-based research, and ongoing technological advancements further support this demand. Rising focus on the development of point-of-care devices for cell separation is also a major opportunity. The growing stem cell banking industry is another positive factor. However, high cost of cell separation instruments and lack of infrastructure for stem cell banking in developing nations limits market expansion to some extent.

Cell Separation Market Concentration By Players

To learn more about this report, Request sample copy

Top Strategies Followed by Global Cell Separation Market Players

Established Players: Leading companies in the global cell separation market heavily invest in research and development to innovate advanced products. Leading companies prioritize extensive research and development to innovate high-performance products.
- For instance, AstraZeneca announced a US$ 3.5 billion investment in the United States by the end of 2026, focusing on expanding research and manufacturing capabilities, which includes advancements in biotechnology sectors
Mid-Level Players: Companies strive to deliver affordable, high-quality products to attract a wider customer base. Miltenyi Biotec provides kits and reagents for manual cell separation at competitive prices. Stemcell Technologies develops kits and systems optimized for scale and budgets. Beckman Coulter focuses on usability and value with instruments like the CytoFLEX flow cytometer and reagents.
Small-Scale Players: Small players leverage niche expertise. Precision for Medicine specializes in veterinary cell separation. Anthropic focuses on AI-based cell separation tools. Microfluidic Chipshop develops organ-on-chip microfluidic devices for cell research.

Emerging Startups - Cell Separation Industry Ecosystem

Innovative Technologies: Companies like Celularity are developing AI platforms for automated, large-scale isolation of stem cells from placental tissue. CytoReason applies AI to accelerate the discovery of novel cell markers. Resolution Biosciences is commercializing acoustic-based cell sorting platforms for single-cell multi-omics. These technologies could disrupt current solutions and transform cell-based research.
Sustainable Solutions: Bolt Threads creates biodegradable materials like microbial cellulose as an alternative to plastic consumables in cell processing. Circular economy startups like Solugen and Anthropic upcycle industrial waste to produce reagents and media for cell culture, contributing to sustainability goals. Their solutions could boost the adoption of greener technologies.
Market Contribution: Partnerships with established companies or research institutions are common among startups to drive technological and sustainable innovation. For instance, Ring Therapeutics engaged a global ecosystem of R&D experts to expand the potential of its Anellogy platform, aiming to accelerate the clinical translation of its therapeutics.

Key Developments:

In November 2024, Akadeum Life Sciences, a leader in buoyancy-based cell separation technology, expanded its product portfolio with a new human B cell isolation kit and updated protocols for existing isolation kits. Unveiled at the 105th American Association of Immunologists annual meeting, the new products leverage Akadeum’s microbubble-based Buoyancy-Activated Cell Sorting (BACS) technology, which eliminates the need for columns or magnets, offering higher yields, faster processing, and simpler workflows.
In April 2024, GenScript, a life sciences company, and Multiply Labs, a company in robotics, announced a strategic partnership to automate the cell isolation phase of cell therapy manufacturing. This collaboration aims to streamline the labor-intensive process of isolating cells using immunomagnetic beads, which currently involves manual handling of complex closed-system consumables, ensuring greater efficiency and precision.
In November 2023, LevitasBio, a life sciences company, partnered with Planet Innovation, a healthtech innovation and manufacturing company, to develop LeviCell EOS system, an advanced cell isolation and enrichment platform launched mid-year with strong early adoption in top U.S. research labs. Building on Levitation Technology from LeviCell 1.0, the EOS enriches cell populations without stress or damage, delivering higher-quality samples for research in cell and gene therapy, pharmaceuticals, and more.
In January 2022, Sony Corporation, a Japan-based manufacturer of consumer electronics products, unveiled CGX10, a high-speed, high-purity Cell Isolation System designed for closed-system operation. This ensures sterile cell sorting and analysis, crucial for fields like cell-based immunotherapy, which is increasingly used to treat cancer and autoimmune disorders.